New Study: Moldova Pharmaceuticals & Healthcare Report Q4 2015

Moldova is heavily dependent on the success of outside sou rces, such as the European and Russian economy. In this regard, Moldova ' s economy is continuing to suf fer greatly from the declining e uro vs the US d ollar and GBP combined with the full force of Western sanctions against the Russian Economy, as well as the drop in global oil prices. Indeed, a sluggish road is ahead for market growth in Moldova. However, increased purchasing power from outside investors could spark premature growth.

Headline Expenditure Projections

Pharmaceuticals: MDL4.75bn (USD340mn) in 2014 to MDL5.20bn (USD297mn) in 2015; +9.5% in local currency terms and -12.1% in US dollar terms.
Healthcare: MDL12.87bn (USD920mn) in 2014 to MDL14.40bn (USD820mn) in 2015; +11.8% in local currency terms and -10.2% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/1047957_moldova_pharmaceuticals.aspx?afid=301

Risk/Reward Index : Moldova stands in last position in our Q315 Pharmaceutical Risk/Reward Index, posting below regional average scores for every indicator. In Q315, the country scores 33.0 and stands in 20th out of the 20 markets in Central and Eastern Europe (CEE), down one place from the previous quarter.

Key Trends And Developments

In May 2015, the Moldovan Ministry of Health reviewed the prices of 277 drugs following the appreciation of the national currency against the euro, reports IPN. The ministry has reduced prices, by 5.4% on average, on drugs such as Pimafucin (natamycin), Ribomustin (bendamustine), Lopril (lisinopril) and Ampril (Enalapril). The order on the revision of drug prices will become effective when it is published in the Official Gazette.

The Moldova Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Moldova Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Moldova pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Moldova, to test other views - a key input for successful budgeting and strategic business planning in the Moldovan pharmaceutical and healthcare market.
* Target business opportunities and risks in the Moldovan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Moldova.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015